CJC-1295 won't be found on pharmacy shelves in Nekoř or anywhere else for that matter — it's a research compound distributed through a dedicated online market. This concentration of supply in online vendors is ultimately a quality advantage — top vendors distinguish themselves through rigorous testing in ways no local retailer can match. What reliably differentiates top CJC-1295 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for contamination assurance. The sections below cover what Nekoř researchers need to know about sourcing, verifying, and handling CJC-1295 for research purposes.
Understanding CJC-1295 — Biology & Evidence
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Nekoř researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Buying CJC-1295: Quality Markers to Look For
Before evaluating any specific vendor, establish a quality benchmark — so you can tell whether a COA is complete and credible. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from microbial contamination can trigger severe inflammatory responses even at very low concentrations. Signs of a credible vendor beyond COA quality: documented vendor history spanning multiple years, customer service that can discuss analytical methods, and temperature-appropriate packaging with desiccant. Keep lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the amount needed for the near-term protocol and keep the remainder frozen.
Order CJC-1295 — ships to Nekoř
COA-verified · International tracking · Research grade
All use of CJC-1295 in Nekoř or anywhere must be research use only — this compound is not approved for therapeutic human application, and all handling should adhere to research compound handling standards. Storage requirements for CJC-1295: lyophilised powder at freezer temperature, reconstituted solution refrigerated at 2-8°C and used within 30 days; reconstitute only with bacteriostatic water. The most significant preventable safety hazard in CJC-1295 research is endotoxin contamination from poor sourcing — a documented endotoxin result in your specific batch certificate is the direct mitigation for this hazard. PubMed and related preprint servers provide the most complete literature coverage for CJC-1295 research; favour indexed journal publications over preprints over unreviewed preprints or forum reports.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
